Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly ...

Cardiac transthyretin amyloidosis (also called ATTR amyloidosis cardiomyopathy or ATTR-CM) is a progressive disease and a cause of fatal heart failure resulting from extracellular myocardial ...

On May 19, BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced promising results from its Phase 3 trial of Acoramidis, showing its ability to increase serum transthyretin (TTR) levels and significantly ...

ATTR amyloidosis results from the buildup of transthyretin in the body. It can be inherited or acquired and can affect your heart, kidneys, and nervous system. While there’s no cure, treatment can ...

Novo Nordisk has struck a $1.2 billion deal to buy Prothena’s ATTR amyloidosis program, which was stalled by the pandemic last year. The deal will see Novo pay $100 million in upfront and near-term ...